Supervisory Board

Dr. Michael Hoffmann was named chairman of the Novaliq supervisory board in 2022. Michael is a lawyer and since 2017 a member of the management board of the Hopp Family Office. He serves in various advisory and supervisory boards. He holds a Master degree (LL.M.) from the London School of Economics and a Ph.D. in law from the University of Trier.

Dr. Mathias Hothum is managing director of dievini GmbH & Co. KG, advisors in health sciences. Dievini manages the biotech investments of SAP co-founder Dietmar Hopp. He received his degree in Economics from the University of Mannheim and his doctorate from the University of Magdeburg.
For the past 20 years, he has worked as an economist in the sectors of healthcare, health services and life sciences. Mathias specializes in pricing, reimbursement and the evaluation of mid-sized companies, as well as of publicly-owned/market-listed companies. He is the owner and founder of HMM Consulting. Furthermore, he is Chairman of the board of joimax GmbH and board member of CureVac AG, Heidelberg Pharma AG, Apogenix AG, Molecular Health GmbH and Novaliq GmbH.

Dr. Klaus Schollmeier is an advisor to the Pharma/Biotech industry and member of the board/chairman of several Biotech companies including Tacalyx GmbH (Germany), Modra Pharmaceuticals (Netherlands), Affiris Pharma (Austria), CureVac AG (Germany) and Eternygen GmbH (Germany). He advices and mentors a number of start-up companies in Europe as Entrepreneur in residence and business angel, including BASF’s company builder Chemovator. Klaus was CEO SuppreMol GmbH from 2013 until 2015, when the company was sold to Baxalta. Prior to that, he served as CEO Santhera (Switzerland) from 2004 to 2011 and their chairman of the board until 2013. Prior to joining the biotechnology industry in 2003, he served as managing director of the healthcare/biotechnology group at ING-BHF Bank for ING Group Europe having previously spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott.
Klaus holds a Ph.D. in biology from the University of Düsseldorf, Germany, and in 1991, he became an adjunct research associate professor at the Boston University Medical School, Massachusetts.